An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Trial Profile

An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms DASISION
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 25 Jun 2017 Results of retrospective analysis of five-year molecular and cytogenetic response rates presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results of a retrospective analysis assessing the impact of baseline comorbidities and patient age on 5-year safety and efficacy, presented at the 22nd Congress of the European Haematology Association
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top